Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
NCT01009060
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
GSK239512
DRUG:
Placebo
Sponsor
GlaxoSmithKline